Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sov i SNOO Smart Sleeper Bassinet hos for tidligt fødte børn

1. september 2026 opdateret af: Rakesh Sahni, Columbia University

Effekten af ​​sovemiljø på søvn-vågen organisering hos præmature spædbørn

The goal of this clinical trial is to compare sleeping in a SNOO Smart Sleeper bassinet (SNOO) with sleeping in traditional bassinet conditions in premature infants. The main questions it aims to answer are:

  1. Do preterm infants who sleep in the SNOO have more quiet sleep?

  2. Do preterm infants who sleep in the SNOO have improved vital signs?

    • Participants will spend two separate three-hour periods sleeping in either a SNOO (which plays white noise and rocks from side-to-side) or in a SNOO that remains off (does not play white noise and does not move). There will be at least one week separating these sleep assessments.
    • Participants will have their sleep stage and vital signs monitored (heart rate and oxygen levels).
    • Participants will also wear two stickers on their forehead that measure brain oxygen levels (NIRS) and brain waves (EEG).

There is a chance that the infant may experience more restful sleep and improved vital signs during the 2 sleep assessments.

Studieoversigt

Detaljeret beskrivelse

Sleep plays an important role in the brain growth and development of preterm infants. Neonatal sleep is made up of three stages of sleep: quiet sleep, active sleep, and transitional sleep. Poor sleep can be a result of premature birth itself as well as from simply being in the neonatal intensive care unit (NICU) environment. The interruptions that these infants are exposed to include frequent cares, physical exams, lights, and noises.

The investigators are interested in the potential positive effects on sleep of recreating the environment of the womb. The SNOO is a bassinet that uses the combination of a secure swaddle, white noise, and gentle rocking movements to mimic the conditions that infants were exposed to in the uterus before being born. The investigators are interested in studying how recreating this environment of "within the womb" impacts the sleep-wake cycles of premature infants. To do this, the investigators will measure the amount of time that premature infants spent asleep versus awake while in the SNOO through behavior observations, electroencephalogram (brain activity monitoring), and vital signs. The investigators hypothesize that sleeping in the SNOO will increase the amount of time that the premature infants spend in quiet sleep and will improve their vital signs.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10032
        • Morgan Stanley Children's Hospital Neonatal Intensive Care Unit, NewYork Presbyterian

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 uge til 2 måneder (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Inpatients at the Morgan Stanley Children's Hospital NICU.
  • Singleton gestation.
  • Gestational age 28w0d to 36w6d at birth.
  • Postmenstrual age greater than 35 weeks at the time of the intervention.
  • Weight greater than 1.8 kg and less than 11.3 kg.
  • Stable thermoregulation in an open crib.
  • Stable respiratory status on room air (no nasal cannula or CPAP).
  • Normal head ultrasound (if obtained).

Exclusion Criteria:

  • Congenital brain or spinal anomalies.
  • Intracranial hemorrhage.
  • Severe encephalopathy.
  • Known or suspected genetic syndromes that could result in cerebral dysfunction.
  • Airway anomalies that could result in sleep-disordered breathing.
  • Bleeding diatheses.
  • Status post surgery or minor surgical procedures (i.e. inguinal hernia repair, circumcision).
  • Fetal opioid exposure.
  • Administration of sedating agents over the past 24 hours.
  • Ability to independently roll to hands and knees.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: SNOO group

The SNOO Smart Sleeper will be used in accordance with the manufacturer's programming and instructions.

Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The "preemie mode" will be enabled, which caps motion at level 2 out of 5.

Sham-komparator: Traditional bassinet group

The SNOO will remain powered off to mimic the conditions of sleeping in a traditional hospital bassinet.

Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent of Quiet Sleep Time During 3-hour Sleep Assessment
Tidsramme: At baseline sleep assessment, up to 3 hours

Quiet sleep is a marker of sleep maturation and will be measured by the researcher during the 3-hour-long sleep assessments. Quiet sleep defined as eyes closed with predominantly flaccid "rag doll" appearance, body movements limited to startles, and rhythmic jaw jerks lasting 1 to 2 seconds.

At baseline sleep assessment, up to 3 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Heart Rate Variability
Tidsramme: At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)

Heart rate variability is the fluctuation of beat-to-beat heart rate intervals over time and is a marker of autonomic nervous system maturation.

At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)
Change in Cerebral Oxygenation
Tidsramme: At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)

Cerebral oxygenation is a measure of the oxygen content of brain and will be measured by near-infrared spectroscopy (NIRS).

At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)
Change in Oxygen Saturation
Tidsramme: At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)

Oxygen saturation is a measure of the oxygen content of the blood, as measured by pulse oximetry.

At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)
Change in Intermittent Hypoxemic Event Frequency
Tidsramme: At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)

Intermittent hypoxemic events are episodes where oxygen saturation is low for prolonged periods, as measured by pulse oximetry.

At baseline sleep assessment (up to 3 hours) and second sleep assessment (up to 3 hours)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Rakesh Sahni, MD, Columbia University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. marts 2023

Primær færdiggørelse (Faktiske)

31. maj 2024

Studieafslutning (Faktiske)

2. juni 2025

Datoer for studieregistrering

Først indsendt

25. januar 2023

Først indsendt, der opfyldte QC-kriterier

25. januar 2023

Først opslået (Faktiske)

3. februar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner